UCB SA - BNP Paribas Fortis
UCB SA - BNP Paribas Fortis
UCB SA - BNP Paribas Fortis
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Half-Year Report 2009 of the Issuer<br />
Condensed Consolidated income statement Page 12<br />
Condensed Consolidated statement of financial position Page 14<br />
Condensed Consolidated statement of cash flows Page 15<br />
Notes to the Condensed Consolidated interim financil statements Page 17<br />
Other documents incorporated by reference<br />
• Press release of 22 October 2009<br />
• Press release of 5 October 2009: Cimzia®, the only PEGylated anti-TNF, approved in Europe and available in<br />
a syringe designed in partnership with OXO Good Grips®<br />
• Press release of 1 October 2009: <strong>UCB</strong> announces convertible bond offering increased to EUR 500 million<br />
following exercise of over-allotment option<br />
• Press release of 30 September 2009: <strong>UCB</strong> successfully completes its convertible bond offering<br />
• Press release of 30 September 2009: <strong>UCB</strong> announces an increase in the amount of the issuance of its<br />
convertible bond offering to up to EUR 450 million<br />
• Press release of 30 September 2009: <strong>UCB</strong> launches an offer of up to EUR 350 million convertible bonds, due<br />
2015<br />
• Press release of 28 September 2009: <strong>UCB</strong> and AstraZeneca form alliance for the commercialization of<br />
Cimzia® in Brazil<br />
• Press release of 27 August 2009: <strong>UCB</strong> and Immunomedics announce positive results for epratuzumab phase<br />
IIb study in systemic lupus erythematosus (SLE)<br />
• Press release of 24 August 2009: <strong>UCB</strong> and Novartis to expand cooperation in Germany<br />
• Press release of 12 August 2009: <strong>UCB</strong> and its design partners, OXO® and Smart Design, win 2009 "Red Dot:<br />
Communication Design"<br />
• Press release of 31 July 2009: <strong>UCB</strong> progress: new product launches and financials on track<br />
• Press release of 24 July 2009: <strong>UCB</strong> receives CHMP positive opinion on Keppra® for infants and young<br />
children with partial-onset epilepsy<br />
• Press release of 30 June 2009: <strong>UCB</strong> and Biogen Idec discontinue Phase II clinical trial of CDP323<br />
• Press release of 29 June 2009: <strong>UCB</strong> brings Neupro® back to all patients in Europe<br />
• Press release of 29 June 2009: New analysis of pooled clinical data showed VIMPAT® (lacosamide)<br />
significantly improved partial-onset seizure control, increased seizure freedom rates and enhanced patient<br />
function<br />
A11250830/2.25/23 Oct 2009 32
Change language